UNSPSC 51333107: Carvotroline hydrochloride

This classification denotes an antipsychotic agent C18H18FN3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OGU53DND3M, chemically known as 1h-pyrido(4,3-b)indole, 8-fluoro-2,3,4,5-tetrahydro-2-(2-(4-pyridinyl)ethyl)-, monohydrochloride, but more generally known as carvotroline hydrochloride, which bears US NIH Compound Identifier 72037. Most nations, for tariff and trade purposes, schedule carvotroline hydrochloride under HS 29333999 and SITC 51574.

As of Q4 2014, CARVOTROLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CC2C(CC1F)C3C([NH]2)CCN(C3)CCC4CCNCC4.CL.

UNSPSC 51333107 Carvotroline hydrochloride is a Commodity code, but the recent state and local opportunities tagged under it show little activity directly aligned with this specific pharmaceutical. The single recent opportunity explicitly naming this code—Seminole County, Florida's IFB60459723LAS issued June 30, 2026—actually solicits naloxone and drug deactivation systems for community health support, not carvotroline. The broader pharmaceutical procurement activity visible under or near this code span generic multi-source drugs, over-the-counter products, and direct-to-manufacturer prescription programs, suggesting the code may be misapplied or that carvotroline itself sees minimal state and local procurement demand.

The issuing bodies engaging in pharmaceutical procurement at the state and local level include large multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of Minnesota and Oregon), state health agencies (Texas Health and Human Services Commission), and county health departments (Seminole County, Florida). Recent opportunities range from competitive IFB for specific pharmaceutical inventories with quarterly delivery schedules to exploratory Requests for Information on direct-to-manufacturer contracting models. The Minnesota MMCAP RFP for generic pharmaceuticals and OTC products, posted January 20, 2026 with a response deadline of March 26, 2026, represents the largest recent procurement footprint in this category; Texas HHS issued an RFI on April 3, 2026 to assess vendor capability for direct-to-manufacturer prescription programs; and Seminole County's naloxone IFB closed July 26, 2023. Geographic activity centers on Florida, Texas, and Minnesota, with cooperative purchasing extending to Oregon. No recent opportunities explicitly solicit carvotroline hydrochloride.